February 2008
Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p1
Trade Publication
The article reports that Progen Pharmaceuticals Ltd. has provided an update on clinical trial enrollment associated with its phase 3 hepatocellular carcinoma study. The trial has begun initiating sites and is now open for patient enrollment, through a thorough examination of available surgical cases has not yet found any eligible patients who were able to be enrolled by December 31, 2007. The drug maker has received regulatory approval to conduct the phase 3 trial in several countries.


Related Articles

  • Progen initiates Phase III liver cancer study.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p5 

    The article reports on the global Phase III study conducted by Progen Pharmaceuticals Ltd. regarding the efficacy and safety of PI-88, an adjuvant treatment for liver cancer. It was stated that the study, which is called Pathway, is double-blinded, placebo-controlled clinical trial that...

  • Oncology. Galvin, Michael // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p55 

    The article presents information on clinical trials related to oncology that were conducted to test the efficacy of drugs including Almorexant Actilion. Aflibercept Regeneron and Lucanix. Two studies examined aflibercept (VEGF Trap) as a single agent in recurrent ovarian and lung cancers. It was...

  • Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88. Shrine, Jim // BioWorld Today;5/4/2007, Vol. 18 Issue 87, p1 

    The article reports that Progen Pharmaceuticals Ltd. has embarked into financing agreements that will produce about $61 million to fund its Phase III cancer trials. The company has signed an agreement with U.S. institutional and other investors to sell 6.9 million shares for $32.8 million. The...

  • Can ‘phase IV’ work for you? Borfitz, Deborah // Medical Economics;6/6/2003, Vol. 80 Issue 11, p58 

    Focuses on the controversies behind phase IV clinical trials in the U.S. Emphasis on creating a potentiated drug combinations; Collaboration between doctors and pharmaceutical companies to increase drug sales; Quality of drug studies conducted.

  • N.O.'s research facilities prove big draw for clinical drug trials. Kamerick, Megan // New Orleans CityBusiness (1994 to 2008);10/20/2003, Vol. 24 Issue 17, p35 

    Reports on the prevalence of clinical drug trials in New Orleans, Louisiana. Number of trials taking place at the Louisiana State University Health Sciences Center; Impact of the prevalence of clinical trials on the economy of the city; Credibility of academic health science in conducting the...

  • Europe gets nul points for harmony in trials. Schnitzbauer, Andreas // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/30/2009, Vol. 338 Issue 7706, p1302 

    The article explores the problems encountered by the authors in getting approval for their multinational study on rapamycin inhibitor or sirolimus. The study was designed to examine the survival and anti-tumor benefits of sirolimus in patients diagnosed with liver cancer who have received...

  • Global clinical trial laboratories decentralize. Rosenberg, Ronald // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1 

    The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting...

  • The Quality of Registration of Clinical Trials. Viergever, Roderik F.; Ghersi, Davina // PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1 

    Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous...

  • A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Ruperto, Nicolino; Eichler, Irmgard; Herold, Ralf; Vassal, Gilles; Giaquinto, Carlo; Hjorth, Lars; Valls-i-Soler, Adolf; Peters, Christina; Helms, Peter J.; Raymond, Agnès Saint // Archives of Disease in Childhood;Mar2012, Vol. 97 Issue 3, p185 

    The article discusses several national and international paediatric networks that are performing clinical trials in the paediatric population in Europe. It examines the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), an organization establish to investigate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics